Skip to main content
. 2014 Oct 1;124(11):4867–4876. doi: 10.1172/JCI75328

Figure 8. Ibrutinib limits activation of T cells and B cells from patients with active cGVHD.

Figure 8

(A) Primary CD4+ T cells were isolated from patients with active cGVHD, pretreated with 1 μM ibrutinib (or DMSO), and stimulated using anti-CD3 for 6 hours. Graph shows the mean florescence intensity (MFI) for CD69 among CD4+ T cells for each patient. *P < 0.05. (B) B cells isolated from patients with cGVHD were pretreated with 1 μM ibrutinib and stimulated with anti-IgM for 45 minutes. Immunoblot analysis of BTK, ERK, and PLCγ2 was conducted. The densitometric quantification of activated proteins relative to total proteins is provided. Data are representative of 3 experiments on 3 separate patients.